Image Source: AsiaOne
Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-MayGlobeNewswireApril 08, 2020NVX-CoV2373 identified as SARS-CoV-2 candidate for Phase 1 clinical trialIn preclinical studies, NVX-CoV2373 demonstrated high immunogenicity and stimulated high levels of neutralizing antibodiesFirst-in-human Phase 1 clinical trial accelerated to mid-May with preliminary results in JulyGMP clinical production initiated at Emergent BioSolutions with ability to leverage capacity for large scale manufacturingGAITHERSBURG, Md., April 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc.
Source: AsiaOne